跳至主要内容
临床试验/DRKS00004864
DRKS00004864已完成不适用

Are fluoroquinolones teratogenic in humans? Evaluation of the Embryotox patient-database

Pharmakovigilanzzentrum EmbryonaltoxikologieCharité-Universitätsmedizin0 个研究点目标入组 4,745 人开始时间: 2013年4月5日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
4,745

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
one 至 one(—)
性别
Female

入选标准

  • For both cohorts: Prospectively ascertained pregnancies, i.e. neither the outcome of pregnancy nor results of prenatal diagnostics are primarily known, but are ascertained at a later stage.
  • Study group (Fluoroquinolone exposed pregnancies): Pregnant women, who had a systemic exposure to fluoroquinolones (oral or intravenous) between gestational week 2+0 and 12+6 after last menstrual period.
  • Control group: Pregnant women, who were neither exposed to fluoroquinolones nor strong teratogenic or fetotoxic substances. The control group is matched with the study group for year of enrolment.

排除标准

  • Exclusion criteria for the control group are cancer or seizures except preklampsia. Furthermore, the exposure to one of the following substances is an exclusion criteria: Acitretin, carbamazepine, isotretinoin, methotrexate, mycophenolate, phenobarbital, phenprocoumon, phenytoin, valproic acid, warfarin, ACE inhibitors, angiotensin II receptor antagonist.

研究者

发起方
Pharmakovigilanzzentrum EmbryonaltoxikologieCharité-Universitätsmedizin

相似试验